Peptide · Research Monograph · Triple GLP-1/GIP/glucagon receptor agonist peptide

GLP-3 RT

Metabolic Regulation Studies

GLP-3 RT is the research designation for a synthetic triple-receptor agonist peptide. It acts on three receptors at once: GLP-1, GIP and glucagon. Research has examined metabolism, energy use and blood glucose endpoints in study models. Most similar compounds bind only two receptors; the third target is the distinguishing feature.

Formula
C221H342N50O68
Mol. weight
4731.32 Da
Length
39 residues
CAS
CAS 2381089-83-2
View product & pricing → Lot records & COAs

For laboratory research use only - not for human or animal use

GLP-3 RT vial from the Eon Peptides research catalog
GLP-3 RT · 10mg / 15mg / 24mg / 30mg / 48mg / 60mg · catalog photograph
Available in the Eon catalog - GLP-3 RT from $85.00 View certificate of analysisThird-party verified · PDF

Molecular data

Molecular formulaC221H342N50O68
Molecular weight4731.32 Da
SequenceGLP-3 RT - synthetic triagonist peptide; full sequence not disclosed on page
Sequence length39 residues
CAS / identifierCAS 2381089-83-2
Physical formLyophilized powder
Available sizes10mg, 15mg, 24mg, 30mg, 48mg, 60mg

How it works

  1. GLP-1R

    GLP-1 Receptor Agonism

    Binds GLP-1 receptors. Published characterisation describes glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and hypothalamic appetite-pathway signalling. This is the same pathway targeted by GLP-1 S and liraglutide.

    • Glucose-dependent insulin secretion
    • Delayed gastric emptying
    • Central appetite-pathway signalling
  2. GIPR

    GIP Receptor Agonism

    Co-agonism at GIP receptors is studied for interaction with GLP-1 signaling, lipid metabolism and adipose tissue remodeling. This dual GLP-1/GIP mechanism is shared with GLP-2 TZ, but GLP-3 RT adds a third target.

    • Insulin secretion under GIP co-agonism
    • Lipid metabolism endpoints
    • Adipose tissue signaling
  3. GCGR

    Glucagon Receptor Agonism

    The unique third target - glucagon receptor activation, studied in relation to hepatic energy expenditure, fatty acid oxidation and thermogenesis. This differentiates GLP-3 RT from all dual agonists in receptor coverage.

    • Hepatic energy expenditure measured
    • Fatty acid oxidation measured
    • Thermogenic pathway activation

What the research shows

  1. Metabolic

    Metabolic Receptor Research

    Triple receptor engagement at GLP-1, GIP and glucagon receptors is the focus of metabolic research on this compound.

  2. Endocrine

    Glycemic Pathway Research

    Glycemic endpoints including HbA1c and fasting glucose are among the measures examined in metabolic research on this compound.

  3. Hepatic

    Hepatic Lipid Models (MASLD/MASH)

    Hepatic lipid content is an endpoint reported for this compound in preclinical and early clinical literature, within metabolic dysfunction-associated steatotic liver disease research.

  4. Comparative

    Triple vs Dual Agonism

    GLP-3 RT is characterised alongside other glucagon receptor agonists including survodutide, mazdutide and cotadutide, which differ in receptor coverage.

Specification

Compound ClassTriple GLP-1/GIP/Glucagon receptor agonist
Research NameGLP-3 RT
TargetsGLP-1R + GIPR + GCGR
FormLyophilized powder
Purity≥99% (HPLC verified)
TestingThird-party HPLC, Mass Spec, Endotoxin
Storage-20°C for long-term stability
SolubilityWater-soluble
COAIncluded with every order
Stability24 months from manufacture date when stored properly
AppearanceWhite to off-white powder
Molecular FormulaAvailable on request

How it's tested

Every lot of GLP-3 RT released to the catalog carries a third-party certificate of analysis. 16 documented lots are on file for this compound, with reported HPLC purity from 99.00% to 99.96% (mean 99.70%), issued by Accurate Test Labs, Freedom Diagnostics and pH Solutions. 13 of 16 certificates record identity as confirmed.

Documented lots
16
Reported purity
99.00% to 99.96%
Mean purity
99.70%
Issuing labs
Accurate Test Labs, Freedom Diagnostics, pH Solutions

All certificates in the COA library →

Frequently asked questions

What is GLP-3 RT?

GLP-3 RT is a triple hormone receptor agonist. It binds three receptors: GLP-1 (appetite and insulin signalling), GIP (metabolic signalling) and glucagon (energy metabolism). That receptor coverage distinguishes it from single-agonists like GLP-1 S and dual-agonists like GLP-2 TZ.

How does GLP-3 RT differ from GLP-1 S and GLP-2 TZ?

GLP-1 S targets GLP-1 only. GLP-2 TZ targets GLP-1 + GIP (dual agonist). GLP-3 RT targets GLP-1 + GIP + Glucagon (triple agonist). The distinction is receptor coverage.

What is the current development status of GLP-3 RT?

GLP-3 RT remains an investigational compound. It is not approved by the FDA or any regulatory agency for human use, and it is supplied on eonpeptides.com exclusively for in vitro laboratory research. No clinical endpoint is offered as a property of this material.

Is GLP-3 RT FDA approved?

No. GLP-3 RT is currently in Phase 3 clinical trials (the TRIUMPH program). GLP-3 RT is a research compound sold exclusively for in vitro laboratory research. It is not FDA approved and should not be confused with approved medications.

How should GLP-3 RT be stored?

Store lyophilized at -20°C for long-term stability. Protect from direct light and avoid repeated freeze-thaw cycles.

For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.